Table 1.
Demographics and clinical characteristics
| Cases (%) (n=68) |
Control group (%) (n=26) |
DC-CTL group (%) (n=42) | P-Value | |
|---|---|---|---|---|
| Sex | 0.745 | |||
| Male | 59 (86.8%) | 23 (88.5%) | 36 (85.7%) | |
| Female | 9 (13.2%) | 3 (11.5%) | 6 (14.3%) | |
| Age | 0.720 | |||
| <57 | 40 (58.8%) | 16 (61.5%) | 24 (57.1%) | |
| >=57 | 28 (41.2%) | 10 (38.5%) | 18 (42.9%) | |
| Median (range) | 57 (27-80) | 52 (30-80) | 57 (27-78) | |
| Radiotherapy | 0.511 | |||
| Yes | 16 (23.5%) | 5 (19.2%) | 11 (26.2%) | |
| No | 52 (76.5%) | 21 (80.8%) | 31 (73.8%) | |
| TACE therapy | 0.511 | |||
| Yes | 52 (76.5%) | 21 (80.8%) | 31 (73.8%) | |
| No | 16 (23.5%) | 5 (19.2%) | 11 (26.2%) | |
| T stage | 0.596 | |||
| T2 | 11 (16.2%) | 3 (11.5%) | 8 (19.0%) | |
| T3 | 49 (72.1%) | 19 (73.1%) | 30 (71.4%) | |
| T4 | 8 (11.8%) | 4 (15.4%) | 4 (9.5%) | |
| N stage | 0.811 | |||
| N0 | 42 (61.8%) | 17 (65.4%) | 25 (59.5%) | |
| N1 | 22 (32.4%) | 8 (30.8%) | 14 (33.3%) | |
| N2 | 4 (5.9%) | 1 (3.8%) | 3 (7.1%) | |
| M stage | 0.128 | |||
| M0 | 49 (72.1%) | 16 (61.5%) | 33 (78.6%) | |
| M1 | 19 (27.9%) | 10 (38.5%) | 9 (21.4%) | |
| TNM stage | 0.293 | |||
| II | 35 (51.5%) | 12 (46.2%) | 23 (54.8%) | |
| III | 14 (20.6%) | 4 (15.4%) | 10 (23.8%) | |
| IV | 19 (27.9%) | 10 (38.5%) | 9 (21.4%) |